Published in Mol Genet Metab on June 21, 2013
Newborn screening for lysosomal storage diseases. Clin Chem (2014) 1.42
Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations. Mol Genet Metab (2014) 0.95
Chondroitin 6-Sulfate as a Novel Biomarker for Mucopolysaccharidosis IVA and VII. JIMD Rep (2014) 0.93
Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome. Drug Des Devel Ther (2015) 0.89
Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab (2014) 0.89
Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry. J Inherit Metab Dis (2016) 0.88
Establishment of glycosaminoglycan assays for mucopolysaccharidoses. Metabolites (2014) 0.88
Novel heparan sulfate assay by using automated high-throughput mass spectrometry: Application to monitoring and screening for mucopolysaccharidoses. Mol Genet Metab (2014) 0.86
Assay for Glycosaminoglycans by Tandem Mass Spectrometry and its Applications. J Anal Bioanal Tech (2014) 0.86
Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions? Mol Genet Metab (2014) 0.85
Impact of Enzyme Replacement Therapy and Hematopoietic Stem Cell Therapy on Growth in Patients with Hunter Syndrome. Mol Genet Metab Rep (2014) 0.84
Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation. Mol Genet Metab (2014) 0.83
Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations. Expert Opin Orphan Drugs (2015) 0.83
Hematopoietic stem cell transplantation for Morquio A syndrome. Mol Genet Metab (2015) 0.82
Di-sulfated Keratan Sulfate as a Novel Biomarker for Mucopolysaccharidosis II, IVA, and IVB. JIMD Rep (2015) 0.80
Molecular Genetics and Metabolism Report Long-term follow-up of post hematopoietic stem cell transplantation for Hurler syndrome: clinical, biochemical, and pathological improvements. Mol Genet Metab Rep (2015) 0.79
Sanfilippo syndrome: causes, consequences, and treatments. Appl Clin Genet (2015) 0.79
Mucopolysaccharidosis IVA and glycosaminoglycans. Mol Genet Metab (2016) 0.77
Activity of daily living for Morquio A syndrome. Mol Genet Metab (2016) 0.76
Newborn screening and diagnosis of mucopolysaccharidoses: application of tandem mass spectrometry. Nihon Masu Sukuriningu Gakkai Shi (2015) 0.76
Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses. Mol Genet Metab (2016) 0.75
Tandem mass spectroscopy in diagnosis and clinical research. Indian J Clin Biochem (2015) 0.75
A selective screening program for the early detection of mucopolysaccharidosis: Results of the FIND project - a 2-year follow-up study. Medicine (Baltimore) (2017) 0.75
Lysosomal diseases: diagnostic update. J Inherit Metab Dis (2014) 0.75
Biomarkers in Lysosomal Storage Diseases. Diseases (2016) 0.75
Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta (1986) 13.69
Prevalence of lysosomal storage disorders. JAMA (1999) 9.06
Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med (2001) 4.28
Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem (2004) 4.10
The frequency of lysosomal storage diseases in The Netherlands. Hum Genet (1999) 3.54
Analytical and preparative separation of acidic glycosaminoglycans by electrophoresis in barium acetate. Anal Biochem (1968) 2.59
Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I. Clin Chem (2008) 2.48
Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis (2005) 2.40
Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics (2000) 2.40
Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns. Clin Chem (2005) 2.17
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab (2008) 2.04
Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis (2006) 2.01
Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet (1997) 1.98
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr (2004) 1.94
Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. Clin Chem (1989) 1.91
Keratan sulfate: structure, biosynthesis, and function. Glycobiology (2000) 1.87
Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem (1989) 1.83
Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet A (2003) 1.82
A rapid and micro method for separation of acidic glycosaminoglycans by two-dimensional electrophoresis. Anal Biochem (1972) 1.76
Multidisciplinary management of Hunter syndrome. Pediatrics (2009) 1.76
Heparin and heparan sulfate biosynthesis. IUBMB Life (2002) 1.69
Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A (2009) 1.67
Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl (2002) 1.63
The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child (1995) 1.56
Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics (2007) 1.53
Twelve different enzyme assays on dried-blood filter paper samples for detection of patients with selected inherited lysosomal storage diseases. Clin Chim Acta (2006) 1.51
Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr (2013) 1.51
Enzyme replacement in a canine model of Hurler syndrome. Proc Natl Acad Sci U S A (1994) 1.49
High-resolution electrophoresis of urinary glycosaminoglycans: an improved screening test for the mucopolysaccharidoses. Anal Biochem (1982) 1.43
Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat Chem Biol (2012) 1.43
Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clin Chem (2006) 1.38
Sequential thin layer chromatography of urinary acidic glycosaminglycans. Clin Chim Acta (1972) 1.33
Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet (2007) 1.32
Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis (1999) 1.27
Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J Clin Invest (1996) 1.24
Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med (2004) 1.21
Tay-Sachs and Sandhoff diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta (2002) 1.19
Tandem mass spectrometry in the detection of inborn errors of metabolism for newborn screening. Methods Mol Biol (2007) 1.18
Validation of an LC-MS/MS assay for detecting relevant disaccharides from keratan sulfate as a biomarker for Morquio A syndrome. Bioanalysis (2011) 1.17
Development and testing of new screening method for keratan sulfate in mucopolysaccharidosis IVA. Pediatr Res (2004) 1.16
Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis (2013) 1.14
Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci (2009) 1.14
Analysis of unsaturated disaccharides from glycosaminoglycuronan by high-performance liquid chromatography. Anal Biochem (1989) 1.12
Design and synthesis of substrates for newborn screening of Maroteaux-Lamy and Morquio A syndromes. Bioorg Med Chem Lett (2010) 1.11
Quantitation of chondroitin 4-sulfate and chondroitin 6-sulfate in pathologic joint fluid. Arthritis Rheum (1992) 1.10
Cell and gene-based therapies for the lysosomal storage diseases. Curr Gene Ther (2006) 1.10
Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis (2005) 1.10
Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome. Mol Ther (2010) 1.10
Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography-tandem mass spectrometry. J Inherit Metab Dis (2010) 1.09
Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans. J Inherit Metab Dis (2012) 1.09
Diagnostic test for mucopolysaccharidosis. II. Rapid quantification of glycosaminoglycan in urine samples collected on a paper matrix. Clin Chem (1989) 1.03
Analytical method for determination of disaccharides derived from keratan sulfates in human serum and plasma by high-performance liquid chromatography/turbo-ionspray ionization tandem mass spectrometry. Biomed Chromatogr (2007) 1.03
Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS. Mol Genet Metab (1998) 1.03
Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests. Clin Chim Acta (2004) 1.01
Functions of chondroitin sulfate/dermatan sulfate chains in brain development. Critical roles of E and iE disaccharide units recognized by a single chain antibody GD3G7. J Biol Chem (2007) 1.01
New strategies for enzyme replacement therapy for lysosomal storage diseases. Rejuvenation Res (2010) 1.00
Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII. J Inherit Metab Dis (2012) 0.99
Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III. Mol Genet Metab (2012) 0.99
Diagnosis of metachromatic leukodystrophy by immune quantification of arylsulphatase A protein and activity in dried blood spots. Clin Chem (2008) 0.98
Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. Mol Genet Metab (2010) 0.98
Comparison of liquid chromatography-tandem mass spectrometry and sandwich ELISA for determination of keratan sulfate in plasma and urine. Biomark Insights (2011) 0.96
Quantitation of proteoglycans as glycosaminoglycans in biological fluids using an alcian blue dot blot analysis. Anal Biochem (1998) 0.96
Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry. Mol Genet Metab (2009) 0.95
Urinary glycosaminoglycan excretion in healthy subjects and in patients with mucopolysaccharidoses. Arch Med Res (2001) 0.95
Enzyme replacement therapy for the management of the mucopolysaccharidoses. Int J Clin Pharmacol Ther (2009) 0.94
Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice. Mol Genet Metab (2008) 0.94
Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis (2005) 0.94
Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I. J Inherit Metab Dis (2010) 0.93
Urinary excretion of sulphated N-acetylhexosamines in patients with various mucopolysaccharidoses. Biochem J (1985) 0.93
The spot test is not a reliable screening procedure for mucopolysaccharidoses. Clin Chem (1991) 0.92
Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model. Mol Genet Metab (2012) 0.91
An improved method for glycosaminoglycan analysis by LC-MS/MS of urine samples collected on filter paper. Clin Chim Acta (2012) 0.90
Expanded newborn screening: implications for genomic medicine. Annu Rev Med (2008) 0.90
MPS screening methods, the Berry spot and acid turbidity tests, cause a high incidence of false-negative results in sanfilippo and morquio syndromes. J Clin Lab Anal (2002) 0.89
Age related changes in the concentration of serum keratan sulphate in children. J Clin Chem Clin Biochem (1988) 0.88
The quantitative spectrophotometric estimation of total sulfated glycosaminoglycan levels. Formation of soluble alcian blue complexes. Biochim Biophys Acta (1981) 0.88
Variation in immunoreactive trypsinogen concentrations among Michigan newborns and implications for cystic fibrosis newborn screening. Pediatr Pulmonol (2010) 0.84
Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease. J Inherit Metab Dis (2012) 0.84
Quantitation of urinary glycosaminoglycans using dimethylene blue as a screening technique for the diagnosis of mucopolysaccharidoses: an evaluation. Ann Clin Biochem (2007) 0.84
Mass screening test for mucopolysaccharidoses using the 1,9-dimethylmethylene blue method: positive interference from paper diapers. Clin Chim Acta (1997) 0.84
Urinary glycosaminoglycan excretion quantified by an automated semimicro method in specimens conveniently transported from around the globe. Mol Genet Metab (2002) 0.84
Content and sulfation pattern of keratan sulfate in hip osteoarthritis using high performance liquid chromatography. J Rheumatol (2000) 0.83
Immunochemistry of lysosomal storage disorders. Clin Chem (2006) 0.82
Glycosaminoglycans in neonatal urine. Arch Dis Child Fetal Neonatal Ed (2000) 0.81
Binding and detection of glycosaminoglycans immobilized on membranes treated with cationic detergents. Anal Biochem (2000) 0.81
Screening: why, when, and how. Kidney Int (2009) 0.81
Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy. J Mol Neurosci (2000) 0.81
Characterization and determination of human urinary keratan sulfate. Chem Pharm Bull (Tokyo) (1998) 0.80
A reliable spot test for mucopolysaccharidoses. Clin Chem (1971) 0.80
Screening for mucopolysaccharide disorders with the Berry spot test. Clin Biochem (1987) 0.80
A tailored approach to family-centered genetic counseling for cystic fibrosis newborn screening: the Wisconsin model. J Genet Couns (2010) 0.79
Chemical structure of urinary dermatan sulfate excreted by a patient with the Hunter syndrome. Tohoku J Exp Med (1980) 0.79
Fractionation and characterization of urinary heparan sulfate excreted by patients with Sanfilippo syndrome. Tohoku J Exp Med (1984) 0.79
Screening test for urinary glycosaminoglycans and differentiation of various mucopolysaccharidoses. Clin Chim Acta (1985) 0.79
Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): a single dose of galsulfase further reduces urine glycosaminoglycans after hematopoietic stem cell transplantation. Mol Genet Metab (2010) 0.78
The urinary acid mucopolysaccharides in normal male children. Hoppe Seylers Z Physiol Chem (1968) 0.78
The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology (2004) 4.95
Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med (2011) 3.21
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol (2010) 1.98
Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis. Mol Genet Metab (2007) 1.75
The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology (2005) 1.75
Rotavirus-associated encephalopathy with a reversible splenial lesion. Pediatr Neurol (2009) 1.66
Possibility of islet transplantation from a nonheartbeating donor pancreas resuscitated by the two-layer method. Transplantation (2005) 1.65
Predicting success of prospective and retrospective gating with dual-source coronary computed tomography angiography: development of selection criteria and initial experience. J Cardiovasc Comput Tomogr (2008) 1.63
Moving beyond binary grading of coronary arterial stenoses on coronary computed tomographic angiography: insights for the imager and referring clinician. JACC Cardiovasc Imaging (2008) 1.63
Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation (2003) 1.62
Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas (2006) 1.58
Improved outcome of surgical pulmonary embolectomy by aggressive intervention for critically ill patients. Ann Thorac Surg (2011) 1.57
The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther (2012) 1.57
Degradation of amyotrophic lateral sclerosis-linked mutant Cu,Zn-superoxide dismutase proteins by macroautophagy and the proteasome. J Biol Chem (2006) 1.57
Dual-source coronary computed tomography angiography in patients with atrial fibrillation: initial experience. J Cardiovasc Comput Tomogr (2008) 1.56
Image quality and artifacts in coronary CT angiography with dual-source CT: initial clinical experience. J Cardiovasc Comput Tomogr (2008) 1.56
Steroid permeation into the artificial ulcer by combined steroid gel application and balloon dilatation: prevention of esophageal stricture. J Gastroenterol Hepatol (2013) 1.55
Growth charts for patients affected with Morquio A disease. Am J Med Genet A (2008) 1.54
Binding of two flaviolin substrate molecules, oxidative coupling, and crystal structure of Streptomyces coelicolor A3(2) cytochrome P450 158A2. J Biol Chem (2005) 1.52
Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos (2012) 1.48
Pathophysiology of urinary incontinence in murine models. Int J Urol (2012) 1.48
X-linked adrenoleukodystrophy: diagnostic and follow-up system in Japan. J Hum Genet (2010) 1.47
Mass screening for Wilson's disease by measuring urinary holoceruloplasmin. J Pediatr (2002) 1.47
Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif (2002) 1.46
Neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury after cardiopulmonary bypass in the rabbit endotoxemia model. Ann Thorac Surg (2007) 1.45
Automated quantitation of pericardiac fat from noncontrast CT. Invest Radiol (2008) 1.45
White blood cell count is positively associated with benign prostatic hyperplasia. Int J Urol (2013) 1.41
A dietary restriction influences the progression but not the initiation of MSG-Induced nonalcoholic steatohepatitis. J Med Food (2014) 1.41
Endoglin expression in upper urinary tract urothelial carcinoma is associated with intravesical recurrence after radical nephroureterectomy. Int J Urol (2015) 1.40
Platelet preservation with a glycoprotein IIb/IIIa inhibitor in a porcine cardiopulmonary bypass model. Ann Thorac Surg (2005) 1.40
Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg (2013) 1.39
Female urology: what method will you select? Int J Urol (2009) 1.39
Clinical and genetic investigation of 17 Japanese patients with hyperekplexia. Dev Med Child Neurol (2014) 1.39
Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int J Oncol (2008) 1.33
Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet (2007) 1.32
Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab (2012) 1.30
Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab (2010) 1.30
Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. J Biol Chem (2002) 1.29
Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Hum Mutat (2005) 1.27
Corneal thickness in an ophthalmologically normal Japanese population. Ophthalmology (2005) 1.26
Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorder. Mol Genet Metab (2013) 1.26
Algorithm for radiation dose reduction with helical dual source coronary computed tomography angiography in clinical practice. J Cardiovasc Comput Tomogr (2008) 1.24
Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol Pharmacol (2006) 1.24
Cathepsin L stabilizes the histone modification landscape on the Y chromosome and pericentromeric heterochromatin. Mol Cell Biol (2006) 1.22
Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat Res (2003) 1.19
Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med (2011) 1.18
Development and testing of new screening method for keratan sulfate in mucopolysaccharidosis IVA. Pediatr Res (2004) 1.16
Carcinosarcoma of the gallbladder with chondroid differentiation. J Gastroenterol (2002) 1.15
Identification of severe combined immunodeficiency by T-cell receptor excision circles quantification using neonatal guthrie cards. J Pediatr (2009) 1.15
No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol (2005) 1.13
Significant elevation of serum interleukin-18 levels in patients with acute pancreatitis. J Gastroenterol (2006) 1.12
Antioxidant activity of polyphenols in carob pods. J Agric Food Chem (2002) 1.12
Infective endocarditis with cerebrovascular complications: timing of surgical intervention. Interact Cardiovasc Thorac Surg (2011) 1.11
Newborn mass screening and selective screening using electrospray tandem mass spectrometry in Japan. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 1.11
Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice. Mol Ther (2005) 1.10
Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology (2004) 1.10
Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab (2006) 1.10
Loss of Parp-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells. BMC Genomics (2007) 1.10
Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome. Mol Ther (2010) 1.10
Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. Blood (2009) 1.09
Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography-tandem mass spectrometry. J Inherit Metab Dis (2010) 1.09
Specifications of insilicoML 1.0: a multilevel biophysical model description language. J Physiol Sci (2008) 1.08
Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease. Hum Mol Genet (2003) 1.08
Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. J Autoimmun (2008) 1.08
A PEX6-defective peroxisomal biogenesis disorder with severe phenotype in an infant, versus mild phenotype resembling Usher syndrome in the affected parents. Am J Hum Genet (2002) 1.07
Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice. Jpn J Clin Oncol (2011) 1.06
Laparoscopically resected foregut duplication cyst (bronchogenic) of the stomach. Dig Dis Sci (2007) 1.05
Proteomic assessment of a cell model of spinal muscular atrophy. BMC Neurosci (2011) 1.05
Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes. Cardiovasc Res (2003) 1.05
Rectal perforations and fistulae secondary to a glycerin enema: closure by over-the-scope-clip. World J Gastroenterol (2012) 1.05
Giant polypoid basal cell carcinoma with features of fibroepithelioma of Pinkus and extensive cornification. Eur J Dermatol (2004) 1.04
Resection of gallbladder cancer with hepatic metastasis after chemotherapy with gemcitabine. J Hepatobiliary Pancreat Surg (2008) 1.04
The crucial role of caspase-9 in the disease progression of a transgenic ALS mouse model. EMBO J (2003) 1.04
Atelocollagen for protein and gene delivery. Adv Drug Deliv Rev (2003) 1.04
Toxigenic Corynebacterium ulcerans isolated from the domestic dog for the first time in Japan. Jpn J Infect Dis (2009) 1.04
Electron transport pathway for a Streptomyces cytochrome P450: cytochrome P450 105D5-catalyzed fatty acid hydroxylation in Streptomyces coelicolor A3(2). J Biol Chem (2007) 1.02
Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. Mol Genet Metab (2013) 1.02
Application of delayed extraction-matrix-assisted laser desorption ionization time-of-flight mass spectrometry for analysis of sphingolipids in pericardial fluid, peritoneal fluid and serum from Gaucher disease patients. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 1.01